The roles of neoantigen peptides in personalized medicine

Neoantigen based personalized immuno-oncology drugs are a relatively new therapeutic avenue that have shown strong anti-tumor efficacy in the clinic.  Neoantigen peptides have been widely reported to be difficult to synthesize due to their hydrophobicity, length, and charge.  Leveraging extensive peptide synthesis experience GenScript has developed NeoPreTM, a predictive algorithm which is able to determine peptide synthesis difficulty based on sequence alone.  NeoPreTM can then recommend the most efficient approach to successfully synthesizing peptides using one of GenScript’s many synthesis platforms.  This presentation will highlight how NeoPreTM identifies synthesis difficulty and review successful cases of difficult neoantigen peptide synthesis from several researchers.  The presentation will also review how these neoantigen peptides are used during various stages of personalized therapeutic development to increase treatment efficacy.

Learning Objectives:

1. What neoantigen personalized therapeutics are and why they are gaining so much interest amongst the immuno-oncology community 

2. How neoantigen peptides are utilized during personalized therapeutic development

3. How NeoPreTM identifies synthesis difficulty and recommends the most efficient approach for successful neoantigen peptide synthesis